- Home
- SELF vs TCRX Comparison
SELF vs TCRX Comparison
Compare SELF & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SELF | TCRX |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.4M | 49.4M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SELF | TCRX |
|---|---|---|
| Price | $4.97 | $0.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $7.00 |
| AVG Volume (30 Days) | 30.7K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $12,705,245.00 | $10,325,000.00 |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $3.47 | $19.81 |
| P/E Ratio | $44.82 | ★ N/A |
| Revenue Growth | 1.40 | ★ 266.65 |
| 52 Week Low | $4.73 | $0.29 |
| 52 Week High | $5.75 | $2.57 |
Technical Indicators
Market Signals| Indicator | SELF | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 28.67 |
| Support Level | N/A | $0.29 |
| Resistance Level | $5.23 | $1.27 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 29.67 | 50.67 |
Price Performance
Historical ComparisonAbout SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.